Metrics as of 10/16/2026, 08:17 PM (Berlin time), refresh in progress.
Trevi Therapeutics Stock
Trevi Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jennifer L. Good
- Employees
- 34
- Market cap
- $1.7 B
- IPO
- 07/05/2019
The biopharmaceutical company Trevi Therapeutics, Inc. (TRVI) in the healthcare/biotechnology sector primarily focuses on the clinical development of Haduvio. This is an orally administered formulation of nalbuphine for the treatment of neurological conditions such as chronic pruritus or persistent cough in patients…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Trevi Therapeutics stock: price history
1D
-2.1%
1W
-10.2%
1M
-21.1%
6M
-22.2%
YTD
-5.4%
1Y
+11.5%
2Y
+270.3%
5Y
+818.6%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~20% weaker price swings than usual
Trevi Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Business model with weaknesses or early megatrend headwind.
Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for neurologically mediated diseases. The company's lead program is Haduvio, an oral formulation of nalbuphine currently being evaluated in Phase IIb/III clinical trials for the treatment of chronic pruritus and refractory cough in patients with pulmonary fibrosis. Trevi maintains a license agreement with Endo Pharmaceuticals Inc. that grants it rights to various formulations of nalbuphine hydrochloride. The business model centers on clinical development and future commercialization of specialized pharmaceutical products.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Weak
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Trevi Therapeutics
Analyst assessment of Trevi Therapeutics
PRICE TARGET LOW
US$23.00
CONSENSUS
US$29.67
MEDIAN
US$27.50
PRICE TARGET HIGH
US$40.00
1
STRONG BUY
17
BUY
0
HOLD
0
SELL
0
STRONG SELL
18
TOTAL · Buy
As of: 14/08/2026
Trevi Therapeutics stock metrics
P/E
-34.98
P/B
5.75
EV/EBITDA
-31.93
RETURN ON EQUITY
-5.5%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
82.9%
FLOAT SHARES
118,088,251
AVG. DAILY VOLUME (30D)
2,361,805
Insider transactions (SEC)
Heffernan Michael Thomas
Heffernan Michael Thomas
Heffernan Michael Thomas
Heffernan Michael Thomas
Heffernan Michael Thomas
Attention
Price since yesterday: -2.1%
Search (Google Trends)
Institutional holders
Comparable stocks
Frequently asked questions about Trevi Therapeutics stock
What does Trevi Therapeutics do?
Trevi Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jennifer L. Good, the company employs around 34 people.
The IPO was on 07/05/2019; the stock trades on NASDAQ under the ticker TRVI.
What do analysts say about Trevi Therapeutics stock?
18 analysts rate the stock, the consensus is Buy (as of 14/08/2026).
The average price target is US$29.67, ranging from US$23.00 to US$40.00, with a median of US$27.50.
This is an external assessment, not a statement by Market Jury.
When does Trevi Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -20% stronger than usual.
Does Trevi Therapeutics pay a dividend?
No, Trevi Therapeutics currently does not pay a dividend.
Which stocks are comparable to Trevi Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Trevi Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Trevi Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.